

UNISON CLINICAL RESEARCH
CLINICAL TRIALS AS OF 4/19/2011

OPEN AND RECRUITING SITES

ONCOLOGY

1. REO 021- A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin in Patients with Squamous Cell Carcinoma of the Lung
2. MEDI-575 1031- A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
3. M 0902- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Baviximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
4. Pix306- A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
5. REO 018- Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck who have Progressed on or after Prior Platinum-Based Chemotherapy
6. C18083-- A Phase 2 Single Arm Study of Bendamustine in Combination with Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
7. Rab-003-004-_A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse
8. PSHCI 08-009 A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab plus Pemetrexed versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

9. PXD101-CLN-19-A Multi-Center, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL): The BELIEF Trial
10. PCYC-1001-Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment with Gemcitabine
11. AV-951-10-202-A Phase 2 and Biomarker Study of Tivozanib in Subjects with Advanced Renal Cell Carcinoma
12. PPHM 1002-A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Baviximab in Patients with Previously Untreated Stage IV Pancreatic Cancer
13. [Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy]
14. A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
15. A randomized, open-label, phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing patients with metastatic stage IVA and IVB non-squamous NSCLC after induction therapy with carboplatin or cisplatin plus pemetrexed.
16. Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology

NEUROSURGERY

1. A Pivotal Clinical Trial Examining the Safety and Effectiveness of a Hydrogel Surgical Sealant System When Used as a Dural Sealant in Cranial Procedures

CARDIOVASCULAR/VASCULAR/ENDOCRINOLOGY

1. A randomized, double-blinded, placebo-controlled, phase IIa dose-ranging study to assess the safety, pharmacokinetics, and tolerability of multiple doses of sodium nitrite in diabetic patients with peripheral arterial disease (PAD)

ALLERGY/IMMUNOLGY/ASTHMA

1. Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

RECRUITING PATIENTS

ALLERGY/IMMUNOLGY/ASTHMA

1. Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
2. A randomized, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate and inhaled fluticasone propionate in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids
3. A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid- to high-strength inhaled corticosteroids.
4. A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids